Author
Jason R. Westin
Also Known As
ASH 2017). Our goal was to quantify the budgetary impact of axi-cel based on the current U.S. FDA approved label over a three-year time horizon., J Westin, J. R Westin, J. R. Westin, J. Westin, J.R. Westin, JASON R. WESTIN, Jason R Westin, Jason R. Westin, Jason Robert Westin
656
Publications
28.7K
Citations
57
H-Index
104
Concepts
All Affiliations
| # | Concept | H-Index | Publications | Citations |
|---|---|---|---|---|
1 | Medicine | 31 | 64 | 5.2K |
2 | Health Sciences | 19 | 24 | 2.3K |
3 | Cell Biology | 3 | 3 | 169 |
4 | Engineering | 1 | 1 | 223 |
5 | Biostatistics | 1 | 1 | 223 |
Jason R. Westin
×
160
Publications
24.2K
Citations
53
H-Index
| Year | Citations | |
|---|---|---|
Page 1
Page 1